Daniel Lee is a clinical biochemist by training. He received his Ph.D. in pathology at the University of Hong Kong. He has served the pharmaceutical industry for over 25 years, including JNJ, Biogen, GSK, and lately served as general manager and head of site for Roche Pharma R&D in Shanghai, China from 2010. He has broad experience in the drug discovery and development business, familiar in both small molecule and biologic drug discovery and development covering therapeutic areas from CNS, infectious diseases and diabetes complications to oncology and inflammation. Over the years Dr. Lee has published more than 50 papers in Alzheimer’s disease, drug discovery and immunology, actively engaged in teaching, grant/manuscript reviews, and named as a co-inventor for 18 issued patents. He served as head of biomedical technology cluster, Hong Kong Science and Technology Parks, and engaged in repositioning the biomedical technology industry in Hong Kong. He has served as CEO and board director of biotech companies, consultant for institutes and companies, adjunct professor of the Division of Life Science, The Hong Kong University of Science and Technology, and honorary professor of the Faculty of Medicine, The University of Hong Kong.He is a member of the Innovation & Technology Fund Research Projects Assessment Panel and a member and mentor of the Hong Kong Life Science Society (HKLSS). He has been associate vice president and chief innovation and enterprise officer of the Chinese University of Hong Kong since 2019.